Скачать или смотреть XVIVO Perfusion (XVIPF) Q2 2025 Earnings Call

XVIVO Perfusion AB (Nasdaq Stockholm: XVIVO) encountered a challenging Q2 2025 with net sales falling 15.2% YoY to SEK 178.3 million due to weakened lung transplant demand and currency pressure, reflecting an 11% organic decline ([MarketScreener][1], [Investing.com][2]). Despite sales pressure, gross margin held steady at 74% ([Investing.com][3]). Adjusted EBITDA dropped to SEK 23.6 million (13.2% margin), sharply down from SEK 51.1 million (24.3%) in Q2 2024 ([MarketScreener][1]), with net profit sliding to SEK 1.6 million (SEK 0.05/share) . The company highlighted strong segment growth (e.g., US lung +26%, Europe liver +32%, US kidney +47%) and stressed ongoing investments in field force and regulatory milestones like upcoming CE approval for heart technology ([Storage MFN][4]). Management is optimistic about recovery later in the year.

🎧 Tune in for detailed commentary on product launches, margin pressures, commercial expansion, and multi‑organ clinical progress.

📢 Disclaimer: This video includes segments from XVIVO Perfusion’s Q2 2025 earnings call, used for educational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by XVIVO Perfusion is implied. All rights remain with XVIVO Perfusion AB. For more information, visit [https://investor.xvivogroup.com/](https://investor.xvivogroup.com/). For inquiries, contact [[email protected]](mailto:[email protected]).